pSivida Corp. (NASDAQ:PSDV) Files An 8-K Entry into a Material Definitive AgreementItem 1.01.
| (a) | Financial Statements of Business Acquired. |
The financial statements of Icon, including the report of its independent registered public accounting firm, Frank, Rimerman + Co. LLP, required by this item have not been filed on this initial Current Report on Form 8-K but will be filed by amendment on or before June13, 2018.
| (b) | Pro Forma Financial Information. |
The pro forma financial information required by this item has not been filed on this initial Current Report on Form 8-K but will be filed by amendment on or before June13, 2018.
|
Exhibit No. |
Description |
| 4.1 | Warrant to Purchase Common Stock of pSivida Corp., issued March28, 2018, to SWK Funding LLC. |
| 10.1 | Securities Purchase Agreement, dated as of March28, 2018, by and among pSivida Corp. and EW Healthcare Partners, L.P. and EW Healthcare Partners-A, L.P. |
| 10.2 | Second Securities Purchase Agreement, dated as of March 28, 2018, by and among pSivida Corp. and EW Healthcare Partners, L.P. and EW Healthcare Partners-A, L.P. and each other person identified on the pages thereto. |
| 10.3 | Registration Rights Agreement, dated as of March28, 2018, by and among pSivida Corp. and EW Healthcare Partners, L.P. and EW Healthcare Partners-A, L.P. |
| 10.4 | Credit Agreement, dated as of March28, 2018, among pSivida Corp., SWK Funding LLC and the financial institutions party thereto from time to time as lenders. |
| 10.5 | Agreement and Plan of Merger, dated March28, 2018, by and among pSivida Corp., Oculus Merger Sub, Inc., Icon Bioscience, Inc. and Shareholder Representative Services LLC. |
| 99.1 | Press release dated March28, 2018. |
pSivida Corp. ExhibitEX-4.1 2 d560059dex41.htm EX-4.1 EX-4.1 EXHIBIT 4.1 PSIVIDA CORP. WARRANT TO PURCHASE COMMON STOCK Issuance Date: March 28,…To view the full exhibit click here
About pSivida Corp. (NASDAQ:PSDV)
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases.
